Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer

Acquisition of CDK4/6i resistance represents a major clinical challenge. Here, the authors report that inhibition of CK1ε can prevent acquisition of CDK4/6i resistance, potentiating the therapeutic efficacy of CDK4/6i in human breast cancer.

Bibliographic Details
Main Authors:	Fabin Dang, Li Nie, Jin Zhou, Kouhei Shimizu, Chen Chu, Zhong Wu, Anne Fassl, Shizhong Ke, Yuangao Wang, Jinfang Zhang, Tao Zhang, Zhenbo Tu, Hiroyuki Inuzuka, Piotr Sicinski, Adam J. Bass, Wenyi Wei
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-09-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-021-25700-6

id	doaj-88efe8ceb62e4eb287e6888a694cafe6
record_format	Article
spelling	doaj-88efe8ceb62e4eb287e6888a694cafe62021-09-12T11:45:59ZengNature Publishing GroupNature Communications2041-17232021-09-0112111510.1038/s41467-021-25700-6Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancerFabin Dang0Li Nie1Jin Zhou2Kouhei Shimizu3Chen Chu4Zhong Wu5Anne Fassl6Shizhong Ke7Yuangao Wang8Jinfang Zhang9Tao Zhang10Zhenbo Tu11Hiroyuki Inuzuka12Piotr Sicinski13Adam J. Bass14Wenyi Wei15Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical SchoolDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical SchoolDepartment of Liver Surgery & Liver Transplantation, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan UniversityDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical SchoolDepartment of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Blavatnik Institute, Harvard Medical SchoolDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical SchoolDepartment of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Blavatnik Institute, Harvard Medical SchoolDivision of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical SchoolProgram in Cellular and Molecular Medicine, Boston Children’s HospitalDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical SchoolDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical SchoolDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical SchoolDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical SchoolDepartment of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Blavatnik Institute, Harvard Medical SchoolDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical SchoolDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical SchoolAcquisition of CDK4/6i resistance represents a major clinical challenge. Here, the authors report that inhibition of CK1ε can prevent acquisition of CDK4/6i resistance, potentiating the therapeutic efficacy of CDK4/6i in human breast cancer.https://doi.org/10.1038/s41467-021-25700-6
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Fabin Dang Li Nie Jin Zhou Kouhei Shimizu Chen Chu Zhong Wu Anne Fassl Shizhong Ke Yuangao Wang Jinfang Zhang Tao Zhang Zhenbo Tu Hiroyuki Inuzuka Piotr Sicinski Adam J. Bass Wenyi Wei
spellingShingle	Fabin Dang Li Nie Jin Zhou Kouhei Shimizu Chen Chu Zhong Wu Anne Fassl Shizhong Ke Yuangao Wang Jinfang Zhang Tao Zhang Zhenbo Tu Hiroyuki Inuzuka Piotr Sicinski Adam J. Bass Wenyi Wei Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer Nature Communications
author_facet	Fabin Dang Li Nie Jin Zhou Kouhei Shimizu Chen Chu Zhong Wu Anne Fassl Shizhong Ke Yuangao Wang Jinfang Zhang Tao Zhang Zhenbo Tu Hiroyuki Inuzuka Piotr Sicinski Adam J. Bass Wenyi Wei
author_sort	Fabin Dang
title	Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
title_short	Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
title_full	Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
title_fullStr	Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
title_full_unstemmed	Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
title_sort	inhibition of ck1ε potentiates the therapeutic efficacy of cdk4/6 inhibitor in breast cancer
publisher	Nature Publishing Group
series	Nature Communications
issn	2041-1723
publishDate	2021-09-01
description	Acquisition of CDK4/6i resistance represents a major clinical challenge. Here, the authors report that inhibition of CK1ε can prevent acquisition of CDK4/6i resistance, potentiating the therapeutic efficacy of CDK4/6i in human breast cancer.
url	https://doi.org/10.1038/s41467-021-25700-6
work_keys_str_mv	AT fabindang inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT linie inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT jinzhou inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT kouheishimizu inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT chenchu inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT zhongwu inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT annefassl inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT shizhongke inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT yuangaowang inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT jinfangzhang inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT taozhang inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT zhenbotu inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT hiroyukiinuzuka inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT piotrsicinski inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT adamjbass inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT wenyiwei inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer
_version_	1717755490269659136

Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer

Similar Items